Dyslipidemia and cardiovascular complications are comorbidities of nonalcoholic fatty liver
disease (NAFLD), which ranges from simple steatosis to nonalcoholic steatohepatitis …

Background and aims Lipoprotein (a)[Lp (a)] is an important independent cardiovascular risk
factor. However, Lp (a) levels are lower in patients with chronic liver disease than in healthy …

Despite the high prevalence of nonalcoholic fatty liver disease (NAFLD), therapeutic options
and noninvasive markers of disease activity and severity remain limited. We investigated the …

Abstract Background Lipoprotein (a)[Lp (a)] and nonalcoholic fatty liver disease (NAFLD) are
risk factors for cardiovascular diseases. We investigated the relationship between Lp (a) …

Background: Hepatic fibrosis reduces the serum level of lipoprotein (a)[Lp (a)] and may
affect its accuracy in cardiovascular disease prediction of metabolic-associated fatty liver …

Abstract Background and Objectives It is well known that lipid abnormalities exist in the
context of non-alcoholic fatty liver disease (NAFLD). The association between lipoprotein …

Background and aims High lipoprotein (a)[Lp (a)] levels are associated with increased risk of
cardiovascular disease. However, the association between Lp (a) and fatty liver disease …

Background: The hepatic lipidome of patients with early stages of non-alcoholic fatty liver
disease (NAFLD) has been fairly well-explored. However, studies on more progressive …

Serum biomarkers of fibrosis and extracellular matrix remode... : European Journal of
Gastroenterology & Hepatology Serum biomarkers of fibrosis and extracellular matrix …

Background and aims. Non-alcoholic fatty liver disease (NAFLD) is a common, morbid
disease with profound implications for the overall health of the patient. We set out to …